Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: A single-center, phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects

Clinical Therapeutics

Volumn 31, Issue 10, 2009, Pages 2258-2271

  Nunes, Teresa ^a   Machado, Rita ^a   Rocha, José F ^a   Fernandes Lopes, Carlos ^a   Costa, Raquel ^a   Torrão, Leonel ^a   Loureiro, Ana I ^a   Falcão, Amílcar ^b   Vaz da Silva, Manuel ^a   Wright, Lyndon ^a   Almeida, Luis ^a,c   Soares da Silva, Patricio ^a,d  

^a DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

^b 4Health Limited   (Portugal)

^c UNIVERSITY OF AVEIRO   (Portugal)

^d University of Porto   (Portugal)

Author keywords

catechol O methyltransferase; COMT inhibition; levodopa benserazide; nebicapone; Parkinson's disease; pharmacodynamics; pharmacokinetics

Indexed keywords

3 O METHYLDOPA; ADRENALIN; BENSERAZIDE PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; EDETIC ACID; METADRENALIN; NEBICAPONE; PLACEBO; POTASSIUM; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LIVER FUNCTION TEST; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PROTEIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER;

ACETOPHENONES; ADOLESCENT; ADULT; ANTIPARKINSON AGENTS; AREA UNDER CURVE; BENSERAZIDE; CATECHOL O-METHYLTRANSFERASE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ENZYME INHIBITORS; FEMALE; HALF-LIFE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; TYROSINE; YOUNG ADULT;

EID: 71549165763     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.10.019     Document Type: Article

References (24)

1. Bonifácio M.J., Palma P.N., Almeida L., and Soares-da-Silva P. Catechol-O-methyltransferase and its inhibitors in Parkinson's disease. CNS Drug Rev. 13 (2007) 352-379
2. Dingemanse J. Issues important for rational COMT inhibition. Neurology 55 Suppl 4 (2000) S24-S27 discussion
3. Dingemanse J. Issues important for rational COMT inhibition. Neurology 55 Suppl 4 (2000) S28-S32
4. Olanow C.W., and Stocchi F. COMT inhibitors in Parkinson's disease: Can they prevent and/or reverse levodopa-induced motor complications?. Neurology 62 Suppl 1 (2004) S72-S81
5. Widnell K.L., and Comella C. Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations. Mov Disord. 20 Suppl 11 (2005) S30-S37
6. Palma P.N., Bonifacio M.J., Almeida L., and Soares-da-Silva P. Restoring dopamine levels. In: Smith H.J., Simons C., and Sewell R.D. (Eds). Protein Misfolding in Neurodegenerative Diseases: Mechanisms and Therapeutic Strategies (2008), CRC Press, Boca Raton, Fla 415-445
7. Lang A.E., and Lees A. Management of Parkinson's disease: An evidence-based review. Mov Disord. 17 Suppl 4 (2002) i
8. Assal F., Spahr L., Hadengue A., et al. Tolcapone and fulminant hepatitis [published correction appears in Lancet. 1998;352:1478]. Lancet 352 (1998) 958
9. Benabou R., and Waters C. Hepatotoxic profile of catechol-O-methyltransferase inhibitors in Parkinson's disease. Expert Opin Drug Saf. 2 (2003) 263-267
10. Brooks D.J. Safety and tolerability of COMT inhibitors. Neurology 62 Suppl 1 (2004) S39-S46
11. Bonifácio M.J., Vieira-Coelho M.A., and Soares-da-Silva P. Kinetic inhibitory profile of BIA 3-202, a novel fast tight-binding, reversible and competitive catechol-O-methyltransferase inhibitor. Eur J Pharmacol. 460 (2003) 163-170
12. Parada A., Loureiro A.I., Vieira-Coelho M.A., et al. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation. Eur J Pharmacol. 420 (2001) 27-32
13. Almeida L., and Soares-da-Silva P. Pharmacokinetics and pharmacodynamics of BIA 3-202, a novel COMT inhibitor, during first administration to humans. Drugs R D. 4 (2003) 207-217
14. Almeida L., and Soares-da-Silva P. Pharmacokinetic and pharmacodynamic profiles of BIA 3-202, a novel catechol-O-methyltransferase (COMT) inhibitor, during multiple-dose administration to healthy subjects. J Clin Pharmacol. 43 (2003) 1350-1360
15. Almeida L., Vaz-da-Silva M., Silveira P., et al. Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa. Clin Neuropharmacol. 27 (2004) 17-24
16. Silveira P., Vaz-da-Silva M., Almeida L., et al. Pharmaco-kinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide. Eur J Clin Pharmacol. 59 (2003) 603-609
17. Ferreira J., Almeida L., Cunha L., et al. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. Clin Neuropharmacol. 31 (2008) 2-18
18. Loureiro A.I., Bonifácio M.J., Fernandes-Lopes C., et al. Human metabolism of nebicapone (BIA 3-202), a novel catechol-o-methyltransferase inhibitor: Characterization of in vitro glucuronidation. Drug Metab Dispos. 34 (2006) 1856-1862
19. Vieira-Coelho M.A., and Soares-da-Silva P. Ontogenic aspects of liver and kidney catechol-O-methyltransferase sensitivity to tolcapone. BrJ Pharmacol. 117 (1996) 516-520
20. Vieira-Coelho M.A., and Soares-da-Silva P. Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase. Brain Res. 821 (1999) 69-78
21. Gabrielsson J., and Weiner D. Pharmacokinetic-Pharmacodynamic Data Analysis: Concepts and Applications. 2nd ed. (1997), Apotekarsocieteten, Stockholm, Sweden
22. Paija O., Laine K., Kultalahti E.R., et al. Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR. Clin Neuropharmacol. 28 (2005) 115-119
23. Ahtila S., Kaakkola S., Gordin A., et al. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. Clin Neuropharmacol. 18 (1995) 46-57
24. Jorga K., Fotteler B., Sedek G., et al. The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation. J Neurol. 245 (1998) 223-230